Sydney Simpson

Sydney Simpson

Auto-generated profile, based on publicly available information

Sydney Simpson

Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Virology
Verified
Journal Article
Closed access
DPDerek Power
Derek Power
NSNetty Santoso
Netty Santoso
MDMichael Dieringer
Michael Dieringer
JYJack Yu
Jack Yu
HHHuachao Huang
Huachao Huang
JZJian Zhu
Jian Zhu

1 November 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HHHuachao Huang
Huachao Huang
NSNetty Santoso
Netty Santoso
DPDerek Power
Derek Power
SSSydney Simpson
Sydney Simpson
MDMichael Dieringer
Michael Dieringer
JZJian Zhu
Jian Zhu
Our functional genomic RNAi screens have identified the protein components of the FACT (facilitates chromatin transcription) complex, SUPT16H and SSRP1, as top host factors that negatively regulate HIV-1 replication. FACT interacts specifically with histones H2A/H2B to affect assembly and disassembly of nucleosomes, as well as transcription elongation. We further investigated the suppressive role of FACT proteins in HIV-1 transcription. First, depletion of SUPT16H or SSRP1 protein enhances Tat-mediated HIV-1 LTR (long terminal repeat) promoter activity. Second, HIV-1 Tat interacts with SUPT16H but not SSRP1 protein. However, both SUPT16H and SSRP1 are recruited to LTR promoter. Third, the presence of SUPT16H interferes with the association of Cyclin T1 (CCNT1), a subunit of P-TEFb, with the Tat-LTR axis. Removing inhibitory mechanisms to permit HIV-1 transcription is an initial and key regulatory step to reverse post-integrated latent HIV-1 proviruses for purging of reservoir cells. We therefore evaluated the role of FACT proteins in HIV-1 latency and reactivation. Depletion of SUPT16H or SSRP1 protein affects both HIV-1 transcriptional initiation and elongation and spontaneously reverses latent HIV-1 in U1/HIV and J-LAT cells. Similar effects were observed with a primary CD4+ T cell model of HIV-1 latency. FACT proteins also interfere with HTLV-1 Tax-LTR-mediated transcription and viral latency, indicating that they may act as general transcriptional suppressors for retroviruses. We conclude that FACT proteins SUPT16H and SSRP1 play a key role in suppressing HIV-1 transcription and promoting viral latency, which may serve as promising gene targets for developing novel HIV-1 latency-reversing agents.

7 June 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
HHHuachao Huang
Huachao Huang
SLShuai Liu
Shuai Liu
MJMaxime Jean
Maxime Jean
SSSydney Simpson
Sydney Simpson
HHHe Huang
He Huang
JZJian Zhu
Jian Zhu
Although combinatory antiretroviral therapy (cART) is effective to reduce HIV-1 viremia, it does not eliminate HIV-1 infection. HIV-1 remains latent with the presence of cART, impeding the cure of HIV-1/AIDS. Recently, latency-reversing agents (LRAs) have been developed to purge latent HIV-1, providing an intriguing strategy for eradication of residual, latent viral reservoirs. Our earlier studies show that the first-generation, methyl-triazolo bromodomain and extra-terminal domain inhibitor (BETi), JQ1, facilitates the reversal of HIV-1 latency. BETis have recently emerged as a new class of compounds that are promising for HIV-1 “shock and kill” eradication approach. However, due to the stochastic effcts of HIV-1 reactivation (Ho et al, Cell, 2013), JQ1 only modestly reverses HIV-1 latency as a single drug, which complicates the study of the underlining mechanisms. Thus, BETis, which are more potent, easier for synthesis, and with more structural diversity, are currently under active development. One such compound is UMB-32, a novel second-generation, 3,5-dimethylisoxazole BETi based on an imidazo[1,2-a]pyrazine scaffold. We screened 37 UMB-32 derivatives and identified that UMB-136 consistently reactivates HIV-1 in multiple cell models of HIV-1 latency with better efficiency than JQ1 and UMB-32. UMB-136 enhances HIV-1 Tat-LTR mediated transcription and increases HIV-1 viral production. Furthermore, UMB-136 enhances the latency-reversing effect of PKC agonists (prostratin, bryostatin-1) in CD8-depleted PBMCs containing HIV-1 latent reservoirs. Thus, our results illustrate that structurally improved BETis, such as UMB-136, would be useful as promising LRAs for HIV-1 eradication.

17 October 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
MJMaxime J. Jean
Maxime J. Jean
THTsuyoshi Hayashi
Tsuyoshi Hayashi
HHHuachao Huang
Huachao Huang
JBJustin Brennan
Justin Brennan
SSSydney Simpson
Sydney Simpson
JZJian Zhu
Jian Zhu
Despite combination antiretroviral therapy (cART), acquired immunodeficiency syndrome (AIDS), predominantly caused by the human immunodeficiency virus type 1 (HIV-1), remains incurable. The barrier to a cure lies in the virus’ ability to establish a latent infection in HIV/AIDS patients. Unsurprisingly, efforts for a sterilizing cure have focused on the “shock and kill” strategy using latency-reversing agents (LRAs) to complement cART in order to eliminate these latent reservoirs. However, this method faces numerous challenges. Recently, the “block and lock” strategy has been proposed. It aims to reinforce a deep state of latency and prevent sporadic reactivation (“blip”) of HIV-1 using latency-promoting agents (LPAs) for a functional cure. Our studies of curaxin 100 (CBL0100), a small-molecule targeting the facilitates chromatin transcription (FACT) complex, show that it blocks both HIV-1 replication and reactivation in in vitro and ex vivo models of HIV-1. Mechanistic investigation elucidated that CBL0100 preferentially targets HIV-1 transcriptional elongation and decreases the occupancy of RNA Polymerase II (Pol II) and FACT at the HIV-1 promoter region. In conclusion, CBL0100 is a newly identified inhibitor of HIV-1 transcription that can be used as an LPA in the “block and lock” cure strategy.

18 September 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
SSSydney R. Simpson
Sydney R. Simpson
MSMeera V. Singh
Meera V. Singh
SDStephen Dewhurst
Stephen Dewhurst
GSGiovanni Schifitto
Giovanni Schifitto
SMSanjay Maggirwar
Sanjay Maggirwar
Platelets were recently found to harbor infectious HIV virions in infected individuals who are on antiretroviral treatment with poor CD4+ T-cell recovery. In this study, we screened platelets from recently infected individuals, before and after antiretroviral therapy, for the presence of virus and examined platelet activation, as well as CD4+ T-cell recovery. This was followed by in vitro studies assessing platelet–CD4+ T-cell complex formation as a contributing factor to viral transmission. HIV+ platelets were detected in 10 of 10 acutely infected individuals with no prior history of antiretroviral therapy. The percentage of HIV+ platelets dropped significantly after 3 months of antiretroviral therapy in all of the study participants. These individuals also demonstrated significant recovery of CD4+ T cells. Interestingly, the percentage of HIV+ platelets correlated positively with viral load but not with CD4+ T-cell count. Furthermore, we found that platelet activation with soluble CD40L or thrombin receptor activator peptide 6 (TRAP6) increased platelet-virus interactions in vitro. TRAP6-mediated interactions were reduced by platelet antagonists, aspirin, and R406. We demonstrated that platelets transmit the virus to CD4+ T cells, and this transinfection was abolished by inhibiting platelet–T-cell complex formation via exposure to an anti-CD62P antibody. Additionally, treatment with TRAP6 significantly increased the transinfection, which was also inhibited by aspirin and R206. These results reveal that platelets have the potential to promote HIV viral spread during the acute stage of infection, by harboring infectious virus transmitting infection to susceptible CD4+ T cells through complex formation.

1 October 2017 in Antiviral Research
Verified
Journal Article
Closed access
THTsuyoshi Hayashi
Tsuyoshi Hayashi
MJMaxime Jean
Maxime Jean
HHHuachao Huang
Huachao Huang
SSSydney Simpson
Sydney Simpson
NSNetty G. Santoso
Netty G. Santoso
JZJian Zhu
Jian Zhu